POLICYBZR Q4 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,090 Cr
verified against source
Revenue YoY
34%
reported change
EBITDA
₹324 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
PB Fintech delivered a strong Q4 FY24 with health and life insurance combined new premiums growing 53% YoY, driving total insurance premium to INR 5,123 crore and reaching the long-awaited INR 20,000 crore ARR milestone. The company achieved full-year PAT of INR 64 crore (vs loss of INR 488 crore last year), a swing of INR 552 crore, though management noted this was below Yashish Dahiya's expected INR 80 crore due to quarter-on-quarter classification movements and tax impacts. Core online marketplace revenues grew 39% to INR 2,375 crore with Adjusted EBITDA margin expanding from 6% to 14%. Trail revenue surged to INR 577 crore from INR 388 crore, delivering 85% margins and increasingly becoming the profit engine. Paisabazaar grew 22% (guidance was 20%), though management expects moderation to 0-10% growth for at least one more quarter due to process-based, not quality-based, slowdown. CSAT reached record 89%. Guidance emphasizes growth priority over margins; steady-state margin discussion was explicitly avoided as management sees significant runway ahead given current take rates of ~16-17% vs EOM ceiling of 30-35%. Key risks include competitive intensity on POSP (commission-based competition), potential EOM cap impact on broker channel, and execution on health growth sustainability given 53%+ expansion rates.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects Paisabazaar growth to be 0-10% for at least one more quarter due to process-based (not quality-based) tightening that is expected to ease shortly.
- Yashish explicitly stated 'growth is a priority, massive priority' while profit is 'like counting the bogies going through of the train' as renewals drive profitability.
- Sarbvir indicated brand costs increase roughly at half the rate of premium growth, and the company will continue to grow brand spending in FY25 as ROI remains positive.
- New initiatives (including PB Partners) broke even at a contribution level, with PB Partner growing 50% QoQ and expanding to 18,000 PIN codes covering 93% of India.
Risks flagged
- Shreya from CLSA raised concerns that broker commission rates (~16-17% for Policybazaar) may appear higher than other channels when measured by commission-to-premium ratio, potentially triggering EOM cap scrutiny. Management responded that total cost of operation (not just commission) makes Policybazaar the lowest-cost supplier.
- Year-over-year take rates declined due to product mix shift from guaranteed return products to ULIPs in the savings segment. While management views this positively for customers, it impacts near-term revenue recognition.
- Alok acknowledged that POSP business 'essentially competes on commission' unlike Policybazaar's digital platform, creating margin pressure risk as the industry scales under potential EOM caps.
- With health significantly outperforming the 53% combined growth rate, execution risk increases. Management was reluctant to provide specific segment breakdown, making it difficult to assess sustainability of current growth trajectory against market share gains.
Key quotes
- Health and life insurance combined, which is the core of our business and a bulk of our long-term value, had a combined growth of 53% year-on-year in new premiums for the quarter. Our total insurance premium for the quarter was INR 5,123 crores, and that gives us an ARR of INR 20,000 crores, which was also a long-awaited milestone.
- We had aimed for a full-year PAT breakeven, and we are very happy to announce that we achieved that ahead of the target in Q3 itself and have now ended the year with a PAT of INR 64 crores from a loss of INR 488 crores last year. This is a swing of INR 552 crores. I think if you were to ask me my own opinion, I think the INR 64 crores, in my estimate, is a little below where I expected it to be.
- We are at a very, very early stage of evolution. We are solving a pretty big problem. At a fundamental level, the problem we are going to solve is what is the problem in healthcare? It's all about misaligned interests. A person does not want to buy insurance till they need it. By the time they buy insurance, nobody wants to give them insurance. Our endeavor, if you ask us in the long run, is going to be to address all the problems.
Research modules